Get to know our clinical trials
Randomized, open-label, phase 3 clinical trial of MK-2870 in previously treated non-small cell lung cancer with EGFR mutations or other genomic alterations.
THE MAIN OBJECTIVE OF THIS STUDY IS TO COMPARE MK-2870 WITH CHEMOTHERAPY WITH RESPECT TO PFS ACCORDING TO RECIST 1.1 AS ASSESSED BY BICR IN NSCLC WITH EGFR MUTATIONS.
Specialist
Medical Oncology Department
Madrid headquarters
Technical Summary
- RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF MK-2870 VERSUS CHEMOTHERAPY (DOCETAXEL OR PEMETREXED) IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATIONS OR OTHER GENOMIC ALTERATIONS.
- Code EudraCT: 2023-503539-16
- Protocol number: MK-2870-004
- Promoter: Merck Sharp & Dohme, S.A.
- Molecule/Drug: MK-2870, Docetaxel y Pemetrexed
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.